**Table 1.** The demographic characteristics, clinical and laboratory findings of the patients with acute transverse myelitis. A comparison of the groups was made by taking into account the last Rankin scores at follow-up.

|  |  |  |
| --- | --- | --- |
| **Variable** **(mean ± standard deviation or percentage)** | **All patients** | **The last Rankin scores**  |
| **Group of Rankin score <3** | **Group of Rankin score ≥ 3**  | ***p-* value** |
| n | 193 | 125 | 24 |  |
| Age at presentation | 8.9±4.3 median 8.9 | 8.5±4 median 7.7 | 9.9±4.9 median 12 | >0.05 |
| Female /male ratio  | 94/99: 0.95 | 62/63: 0.98 | 10/14: 0.71 | >0.05 |
| Length of stay (days) | 21.7±27 median 13 | 15.5±11.6 median 12 | 45 ±43 median 36 | **<0.001** |
| Follow-up time (months) | 24.5±21.6 median 18 | 25.9±21.8 median 21.5 | 23.2±21.6 median 18 | >0.05 |
| Symptom duration before admission (days) | 6.8±10.4 median 3 | 5.8±7.1 median 3 | 7.5±11.4 median 2 | >0.05 |
| Time to nadir (days) | 4.84±4.79 median 3 | 4.7±3.9 median 3 | 5.26±5.7 median 2 | >0.05 |
| DTR hypoactivity at admission (%) | 43.8 | 47/123, %38.2 | 15/24, %62.5 | **0.028** |
| Rankin scores |  |  |  |  |
|  Initial | 3.6±1.2 median 4 | 3.4±1.2 median 4 | 4.25±1.2 median 5 | **0.001** |
|  At discharge | 2.4±1.4 median 2 | 2±1.1 median 2 | 4.2±0.9 median 4 | **<0.001** |
| At the last follow-up | 1±1.4 median 1 | 0.5±0.7 median 0 | 3.75±0.9 median 3.5 | **<0.001** |
| Neutrophil count (x103/ϻL) | 7.07±4.73 | 6.9±5.1 | 7.7±3.8 | >0.05 |
| Lymphocyte count (x103/ϻL) | 2.6±1.56 median 2.2 | 2.77±1.67 median 2.37 | 2±1.1 median 1.8 | **0.010** |
| Neutrophil to lymphocyte ratio  | 4.06±6.2 median 2.5 | 3.8±6.8 median 2.1 | 5.2±4.4 median 4.1 | **0.013** |
| IgM positivity of recent infection (%) | 16 | 13.7 | 38.9 | **0.018** |
| IgM positivity of CMV (%) | 3.4 | 1.2 | 18.8 | **0.012** |
| Plasmapheresis usage (%) | 27.2 | 19.4 | 62.5 | **0.000** |
| Initial therapy IVMP / IVIG IVMP (%) | 132/30 81.5 | 102/1885 | 14/863.6 | **0.024** |
| Mechanical ventilation required (%) | 12.4 | 8.9 | 25 | **0.035** |
| Prognosis |  |  |  |  |
| Motor deficit (%) | 34.7 | 24.4 | 79.2 | **<0.001** |
| Sensory deficit (%) | 10.6 | 8.7 | 25 | **0.032** |
| Sphincter involvement (%) | 18.2 | 15 | 29.2 | 0.091 |

NOTE: Thanks to the other members of Turkish Pediatric Transverse Myelitis Study Group, whose names are not specified: ‘ Sanem Yılmaz, Nurettin Alıcı, Ülkühan Öztoprak, Pınar Gençpınar, Didem Soydemir, Arzu Ekici, Hande Tosun, Seda Kanmaz, Bilge Özgör, Deniz Yılmaz, Rıdvan Avcı, Hilal Kırkgöz, Çetin Okuyaz, Hepsen Mine Serin, Erhan Aksoy, Defne Alkılıç, Arzu Yılmaz, Dilek Çavuşoğlu, Senem Ayça, Leman Tekin Orgun, Esra Sarıgeçili, Aslı Kübra Atasever, Olcay Güngör, Kıvılcım Gücüyener, Mutluay Arslan, Nergiz Aliyeva, Semra Büyükkorkmaz Öztürk, A.Semra Hız Kurul, Ali Cansu, Kürşat Bora Çarman, Coşkun Yarar, Muzaffer Polat, Ergin Atasoy, Bahadır Konuşkan, İsmail Solmaz, Şeyda Beşen, Ercan Demir, Salih Akbaş, Büşra Kutlubay, Hüseyin Per, Mehmet Canpolat, Hakan Gümüş, Selcan Öztürk, Çelebi Yıldırım.’